Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CANbridge Pharmaceuticals Inc. ( (HK:1228) ).
CANbridge Pharmaceuticals Inc. announced significant progress in its drug pipeline and business operations for the first half of 2025. The company has entered a strategic cooperation with Baheal Medical, enhancing its marketing and distribution capabilities in China, Hong Kong, and Macau. Key product developments include the commercial launch and expanded insurance coverage for Hunterase® and Livmarli®, as well as the marketing approval for Gaurunning®, a new drug for Gaucher Disease. Additionally, CANbridge is advancing its gene therapy program for Duchenne Muscular Dystrophy, having licensed new technology and generated pre-clinical proof-of-concept data.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. The company’s primary products include enzyme replacement therapies and oral solutions targeting conditions such as Mucopolysaccharidosis type II, Alagille syndrome, and Gaucher Disease, with a market focus on Greater China.
Average Trading Volume: 15,177,446
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.16B
For an in-depth examination of 1228 stock, go to TipRanks’ Overview page.